AU7641798A - The use of biologically active substances for influencing the extracellular areaof sensory cells and method for controlling the administration of active substa nces and device used therein - Google Patents

The use of biologically active substances for influencing the extracellular areaof sensory cells and method for controlling the administration of active substa nces and device used therein

Info

Publication number
AU7641798A
AU7641798A AU76417/98A AU7641798A AU7641798A AU 7641798 A AU7641798 A AU 7641798A AU 76417/98 A AU76417/98 A AU 76417/98A AU 7641798 A AU7641798 A AU 7641798A AU 7641798 A AU7641798 A AU 7641798A
Authority
AU
Australia
Prior art keywords
areaof
extracellular
influencing
administration
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76417/98A
Inventor
Marion Sangster Eckmiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU7641798A publication Critical patent/AU7641798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
AU76417/98A 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular areaof sensory cells and method for controlling the administration of active substa nces and device used therein Abandoned AU7641798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997118826 DE19718826A1 (en) 1997-05-05 1997-05-05 Use of biologically active agents to influence the extracellular space of sensory cells and methods for drug administration control
DE19718826 1997-05-05
PCT/EP1998/001951 WO1998050065A2 (en) 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein

Publications (1)

Publication Number Publication Date
AU7641798A true AU7641798A (en) 1998-11-27

Family

ID=7828596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76417/98A Abandoned AU7641798A (en) 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular areaof sensory cells and method for controlling the administration of active substa nces and device used therein

Country Status (5)

Country Link
EP (1) EP0980256A2 (en)
AU (1) AU7641798A (en)
CA (1) CA2288631A1 (en)
DE (1) DE19718826A1 (en)
WO (1) WO1998050065A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1504760B1 (en) * 1998-03-05 2008-07-09 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
FR2784030B1 (en) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med USE OF CALCIUM AND / OR CGMP-DEPENDENT CHANNEL BLOCKERS FOR THE TREATMENT OF RETINE CONDITIONS
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
WO2005056519A1 (en) * 2003-12-12 2005-06-23 Senju Pharmaceutical Co., Ltd. Alpha-ketoamide derivative, and production method and use thereof
JP4758641B2 (en) * 2003-12-12 2011-08-31 千寿製薬株式会社 α-Ketoamide derivative, process for producing the same, and use thereof
DE102009056597A1 (en) * 2009-12-02 2011-06-09 Tobias Brockmann Use of flavin derivatives and their salts for preparing a medicament for the treatment of pathologies of the internal limiting membrane (ILM), and the flavin derivative is riboflavin or roseoflavin
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
WO2020036658A2 (en) * 2018-04-27 2020-02-20 The Johns Hopkins University Drugs promoting retinal rod photoreceptor survival

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995057A (en) * 1974-04-19 1976-11-30 Wilhelm Horrmann Ophthalmological method
US4188394A (en) * 1978-05-08 1980-02-12 Nelson Research & Development Company Ophthalmic composition and method of use
SU1297862A1 (en) * 1980-07-03 1987-03-23 Институт цитологии и генетики СО АН СССР Agent for treatment of pigment degeneration of retina
JPS5718609A (en) * 1980-07-08 1982-01-30 Senjiyu Seiyaku Kk Intraocular hypotensor
JPS5732229A (en) * 1980-08-05 1982-02-20 Eiji Sakata Preventing agent against kinesia
JPS57130923A (en) * 1981-02-07 1982-08-13 Eiji Sakata Remedy and preventive for vertigo
CH658595A5 (en) * 1983-08-17 1986-11-28 Inst Khim Fiz An Sssr RETINO PROTECTOR FOR THE TREATMENT OF EYE DISEASES.
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
WO1990006123A1 (en) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5260059A (en) * 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US5156852A (en) * 1989-04-20 1992-10-20 La Haye Laboratories, Inc. Composition and method for combating macular degeneration
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
JPH04178328A (en) * 1990-11-08 1992-06-25 Unitika Ltd Vascularization-inhibitory agent
JPH04182432A (en) * 1990-11-19 1992-06-30 Toshio Tanaka Calcium-dependent cyclic nucleotide phosphodiesterase inhibitor
WO1993010798A1 (en) * 1991-12-04 1993-06-10 Uab Research Foundation Monoclonal antibody directed against g-cam and method of using it
US5266580A (en) * 1992-01-24 1993-11-30 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol
US5252568A (en) * 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with loxapine
ATE193207T1 (en) * 1992-02-14 2000-06-15 Regeneron Pharma PREVENTION OF INJURY AND DEGENERATION OF PHOTORECEPTORS CAUSED BY NEUROTROPHIC FACTORS
CN1077092A (en) * 1992-04-10 1993-10-13 张勇 A kind of preparation method of beverage caring for eyes
CN1082896A (en) * 1992-07-18 1994-03-02 苏州第六制药厂 Process for preparing dizzy-stopping suppository
JPH06234645A (en) * 1993-02-09 1994-08-23 Toagosei Chem Ind Co Ltd Vasculatization inhibitor
SE9301422D0 (en) * 1993-04-28 1993-04-28 Kabi Pharmacia Ab METHOD AND MEANS FOR INHIBITING POSTERIOR CAPSULE OPACIFICATION
US5421818A (en) * 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
DK0682664T3 (en) * 1993-12-08 2001-07-16 Alcon Lab Inc Compounds with both potent calcium antagonist and antioxidant activity and their use as cytoprotective agents
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
JP2759050B2 (en) * 1994-01-27 1998-05-28 住友製薬株式会社 Pharmaceutical composition for treating sudden deafness
CN1057444C (en) * 1994-03-16 2000-10-18 吴生武 Eyedrops for curing myopia
AU2829395A (en) * 1994-06-16 1996-01-05 Allergan, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
DE69517593T2 (en) * 1995-03-28 2001-03-08 Ferrer Int POLYMORPHES A AND B OF 1- (PIPHENYLMETHYL) -4- [3- (2-PHENYL-DIOXOLAN-2-YL) PROPYL] PIPERAZINE
WO1996036334A1 (en) * 1995-05-19 1996-11-21 University Of East Anglia Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors
EP0840614A1 (en) * 1995-06-13 1998-05-13 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
ATE230275T1 (en) * 1995-10-25 2003-01-15 Senju Pharma Co ANGIOGENSIS INHIBITOR
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
IT1290801B1 (en) * 1996-07-05 1998-12-11 Mendes Srl USE OF ACETYL L-CARNITINE, ISOVALERYL L-CARNITINE, PROPIONYL L-CARNITINE OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS
US6303579B1 (en) * 1996-10-31 2001-10-16 Alcon Laboratories, Inc. Use of calpain inhibitors to treat ocular neural pathology
IT1288399B1 (en) * 1996-12-03 1998-09-22 Sigma Tau Ind Farmaceuti MEDICATION FOR THE THERAPEUTIC TREATMENT OF AGE-RELATED MACULOPATHY, NON-AGE-RELATED MACULOPATHY AND FOR PROPHYLAXIS

Also Published As

Publication number Publication date
WO1998050065A2 (en) 1998-11-12
EP0980256A2 (en) 2000-02-23
WO1998050065A3 (en) 1999-06-10
DE19718826A1 (en) 1998-11-12
CA2288631A1 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
HUP0104993A3 (en) Method and device for controlled delivery of active agents
AU3689595A (en) Device for use in the laser treatment of biological tissue (variants thereof)
AU1970495A (en) Drug delivery device and method of construction
ZA964658B (en) Device for transdermal electrotransport delivery of fentanyl and sufentanil.
DE69524214T2 (en) AZITHROMYCIN CONTAINING PHARMACEUTICAL ADMINISTRATIVE FORMS WITH CONTROLLED DELIVERY OF ACTIVE SUBSTANCES
AU7361898A (en) Ophthalmologic insertor apparatus and methods of use
IL127189A0 (en) Compositions methods and devices for the transdermal delivery of drugs
AU4871099A (en) Stent delivery device and method of use
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
AU5561698A (en) Apparatus and system for the telematic control of physiological parameters of patients
AU3683800A (en) Device for the therapeutic and cosmetic photo-processing of biological tissues and method for using the same
EP1114816A4 (en) $g(v)-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
EP0776215A4 (en) Device for delivery of substances and methods of use thereof
AU5783898A (en) Active delivery device and related procedures
PL327767A1 (en) Drugs containing known auxiliary substances and an active substance
GR3035382T3 (en) Active substance combinations comprising pyrethroids and insect-development inhibitors
AU5115999A (en) Surgical support device and method of using the same
AU4687600A (en) Device and method for the administration of oxygen
ATE442184T1 (en) DEVICE FOR THE IONTOPHORETIC, TRANSDERMAL ADMINISTRATION OF FENTANYL AND SUFENTANIL
EP0960885A4 (en) Depsipeptides and drugs containing the same as the active ingredient
AU7641798A (en) The use of biologically active substances for influencing the extracellular areaof sensory cells and method for controlling the administration of active substa nces and device used therein
AU4650596A (en) Composition and methods for transdermal delivery of acid-labile drugs
AU2617499A (en) Method and device for evaporating liquid oxygen
HUT74608A (en) Biologically active silicon-compounds and their pharmaceutical and cosmetical use
EP1057492B8 (en) Blood-compatible composition and medical device using same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase